Hopp til innhold
NHI.no
Annonse

Testikkelkreft: Diagnosen

Innhold i artikkelen

Testikkelkreft vil oftest kunne påvises som en fast eller hard kul i en testikkel. I noen tilfeller er hele testikkelen fast og forstørret.

Blodprøver

Omkring 60 prosent av kreftsvulstene i testiklene produserer spesielle proteiner, svulstmarkører, som kan påvises i blodet. Det ene heter alfaføtoprotein (AFP), og det andre er koriogonadotropin (hCG). Påvisning av AFP eller hCG hos en yngre mann betyr nesten alltid at det foreligger testikkelkreft. Dog kan man ikke si motsatt at fravær av AFP eller hCG utelukker testikkelkreft, fordi 40 prosent av dem med testikkelkreft ikke produserer disse stoffene.

Annonse

Andre undersøkelser

Ultralydundersøkelse av testiklene fremstiller vevet og gir i nesten samtlige tilfeller sterke holdepunkter for kreftdiagnosen. Dersom det er mistanke om testikkelkreft, tas det vevsprøve fra testikkelen mens pasienten er i full narkose. Etter at diagnosen er stilt, tas det røntgen av lungene og CT av buken og lungene for å se etter tegn til spredning. Unntaksvis gjøres MR.

Vil du vite mer

Dette dokumentet er basert på det profesjonelle dokumentet Testikkelkreft . Referanselisten for dette dokumentet vises nedenfor

  1. Horwich A, Shipley J, Huddart R. Testicular germ-cell cancer. Lancet 2006; 367: 754-65. PubMed
  2. Sachdeva K. Testicular cancer. Medscape, last updated Dec 18, 2018. emedicine.medscape.com
  3. Sobin LH, Witterkind C: TNM classification of malignant tumours., UICC Wiley-Liss, 2007.
  4. International Germ Cell Consensus Classification: a prognostic factor- based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol 1997; 15: 594-603. PubMed
  5. Kreftregisteret. Cancer in Norway 2018. Oslo: Kreftregisteret, 2019. www.kreftregisteret.no.
  6. Chia VM, Quraishi SM, Devesa SS, Purdue MP, Cook MB, McGlynn KA. International trends in the incidence of testicular cancer, 1973-2002. Cancer Epidemiol Biomarkers Prev. 2010 May. 19(5):1151-9.
  7. Helsedirektoratet. Nasjonalt handlingsprogram med retningslinjer for diagnostikk, behandling og oppfølging av testikkelkreft. 2015. www.helsebiblioteket.no
  8. Daugaard KG, von der Maase H. Cancer testis. Ugeskr Læger 2002; 164: nr. 23.
  9. Ekbom A, Richiardi L, Akre O, Montgomery SM, Sparén P. Age at immigration and duration of stay in relation to risk for testicular cancer among Finnish immigrants in Sweden. J Natl Cancer Inst 2003; 95: 1238 - 40. PubMed
  10. Hoei-Hansen CE, Nielsen JE, Almstrup K, et al. Transcription factor AP-2gamma is a developmentally regulated marker of testicular carcinoma in situ and germ cell tumors. Clin Cancer Res 2004; 10: 8521-30. PubMed
  11. Hoei-Hansen CE, Rajpert-De Meyts E, Daugaard G et al. Carcinoma in situ testis, the progenitor of testicular germ cell tumours: a clinical review. Ann Oncol 2005; 16: 863-8. PubMed
  12. Skakkebæk NE, Rajpert-De Meyts E, Main KM. Testicular dysgenesis syndrome: an increasingly common developmental disorder with environmental aspects. Hum Reprod 2001; 16: 972-8. PubMed
  13. Jacobsen R, Bostofte E, Engholm G, Hansen J, Olsen JH, Skakkebaek NE, et al. Risk of testicular cancer in men with abnormal semen characteristics: cohort study. . BMJ 2000; 321: 789-92. PubMed
  14. Hemminki K, Chen B. Familial risks in testicular cancer as aetiological clues. Int J Androl 2006; 29:205. PubMed
  15. Levin HS. Tumors of the testis in intersex syndromes. Urol Clin North Am 2000; 27: 543-51. PubMed
  16. Shephard EA, Hamilton WT. Selection of men for investigation of possible testicular cancer in primary care: a large case-control study using electronic patient records. Br J Gen Pract 2018. pmid:29970393 PubMed
  17. Oldenburg J, Lehne G, Fosså S. Testikkelkreft. Tidsskr Nor Legeforen 2008; 128: 457-60. PubMed
  18. von Eyben FE, Madsen EL, Blaabjerg O et al. Serum lactate dehydrogenase isoenzyme 1 in patients with seminoma stage I followed with surveillance. Acta Oncol 2002; 41: 77-83. PubMed
  19. Hain S, O'Doherty M, Timothy A, Leslie M, Harper P and Huddart R. Fluorodeoxyglucose positron emission tomography in the evaluation of germ cell tumours at relapse. Br J Cancer 2000; 83: 863-9. PubMed
  20. Lassen U, Daugaard G, Eigtved A, Hojgaard L, Damgaard K and Rorth M. Whole-body FDG-PET in patients with stage I non-seminomatous germ cell tumours. Eur J Nucl Med Mol Imaging 2003; 30: 396-402. PubMed
  21. Horwich A, Shipley J, Huddart R. Testicular germ-cell cancer. Lancet 2006; 367: 754-65. PubMed
  22. Venkitaraman R, Johnson B, Huddart RA et al. The utility of lactate dehydrogenase in the follow-up of testicular germ cell tumours. BJU Int 2007; 100: 30-2. PubMed
  23. Krege S, Beyer J, Souchon R, et al. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EHCCCG): Part I. European Urology 2008; 53: 478-96. PubMed
  24. Krege S, Beyer J, Souchon R, et al. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EHCCCG): Part II. European Urology 2008; 53: 497-513. PubMed
  25. Einhorn LH, Williams SD, Chamness A et al. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N Engl J Med 2007; 357: 340-8. New England Journal of Medicine
  26. Brydoy M, Oldenburg J, Klepp O et al. Self-reported paresthesias, Raynaud’s phenomena, tinnitus, and hearing impairment in a large cohort of long-term testicular cancer (TC) survivors. J Clin Oncol (Meeting Abstracts) 2006; 24: 4547. PubMed
  27. Zagars GK, Ballo MT, Lee ML and Strom SS. Mortality after cure of testicular seminoma. J Clin Oncol 2004; 22: 640-7. PubMed
  28. Choo R, Thomas G, Woo T et al. Long-term outcome of postorchiectomy surveillance for stage I testicular seminoma. Int J Radiat Oncol Biol Phys 2005; 61: 736-40. PubMed
  29. Warde P, Chung P, Sturgeon J et al. Should surveillance be considered the standard of care in stage I seminoma?. J Clin Oncol 2005; 23 (suppl 16): 4520.
  30. Oliver RTD, Mason MD, van der Maase H et al. Radiotherapy versus single dose carboplatin in adjuvant treatment of stage I testicular seminoma: a randomised trial. Lancet 2005; 366: 293-300. PubMed
  31. Warde P, Gospodarowicz M. Adjuvant carbopaltin in stage I seminoma. Lancet 2005; 366: 267-8. PubMed
  32. Rosendal S, Kristensen E, Giraldi AGE. Seksuelle dysfunktioner hos mænd, der er behandlet for testikelkræft. Ugeskr Læger 2007; 169: 3941. PubMed
  33. Nazareth I, Lewin J, King M. Sexual dysfunction after treatment for testicular cancer - a systematic review. J Psychosom Res 2001; 51: 735-43. PubMed
  34. Fung C, Fossa SD, Williams A, Travis LB. Long-term morbidity of testicular cancer treatment. Urol Clin North Am 2015; 42: 393-408. PMID: 26216826 PubMed
Annonse
Annonse